$ELAN

VanHimbergen Robert M purchased $97K of ELAN

VanHimbergen Robert M (EVP and CFO) purchased 4,200 shares of Elanco Animal Health Inc (ELAN) at $23.08 on 2026-08-07.

Original reporting
SEC EDGAR · VanHimbergen Robert M
Published Aug 10, 2026, 8:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ELAN
Bullish
low confidence
Mentioned
$ELAN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELANBullishLow
01

Why it matters

The newest information is the CFO’s open-market purchase details (shares, price, total value, and post-transaction holdings).

02

Market read

This is a fresh insider-buy disclosure that may slightly support sentiment, but it does not introduce new operational or financial guidance.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it still provides no rationale for the buy, and the dollar amount is relatively small versus company market cap.

Relevance 4/10Novelty 5/10Timing: filed after-hours on 2026-08-10 (SEC Form 4 disclosure)

Background

The article is an SEC Form 4 insider transaction disclosure for Elanco Animal Health Inc.

Company-level read

Ticker impact

$ELANBullishLow confidence
Context

Elanco Animal Health CFO VanHimbergen bought 4,200 shares open-market at $23.0776 on 2026-08-07, filing disclosed 2026-08-10.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction with a defined trade size and price, but it does not include new company guidance, contracts, litigation, or operational changes.

Market effects

No direct sector read-through; this is a single-company insider transaction without broader industry information.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine liquidity or diversification actions and do not necessarily reflect a change in fundamentals.

Key entities

  • Elanco Animal Health Inc

    Subject of the Form 4 insider transaction disclosure.

  • VanHimbergen Robert M

    EVP and CFO who reported the open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ELANLow

Wrap up: Elanco expands Kansas biologics plant, and other news

Elanco Animal Health completed a $120 million expansion of its biologics plant in Kansas, increasing capacity fourfold. The company plans to invest an additional $30 million by 2028, aiming for unconstrained supply of its dermatology product Befrena by early 2027, as demand is twice expectations.

$ELANLow

Elanco completes $120 million expansion of its Kansas biologics plant

Elanco Animal Health completed a $120M expansion of its Kansas biologics plant, increasing production capacity 4x. The site now serves as the company's center for monoclonal antibody (mAb) manufacturing, with plans for an additional $30M investment by 2028. Elanco acquired the site in 2021 and has since grown its workforce from 30 to over 200 employees. The expansion supports products like Trutect and Befrena, with demand for the latter exceeding expectations.

$ELANMed

Elanco rating upgraded by Fitch on deleveraging progress

Fitch Ratings upgraded Elanco Animal Health’s (NYSE:ELAN) Long-Term Issuer Default Rating to BB+ from BB and raised senior secured to BBB- from BB+ and senior unsecured to BB+ from BB, with a stable outlook. Fitch cited balance-sheet deleveraging, share gains, and cash flow. It projects EBITDA leverage below 3.5x, debt down about $650M since 2024, and free cash flow rising from $345M (2026) to ~$575M (2028).